Kirk Robarge

2.3k total citations
26 papers, 1.0k citations indexed

About

Kirk Robarge is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Kirk Robarge has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Organic Chemistry and 4 papers in Computational Theory and Mathematics. Recurrent topics in Kirk Robarge's work include Carbohydrate Chemistry and Synthesis (6 papers), Computational Drug Discovery Methods (4 papers) and Melanoma and MAPK Pathways (4 papers). Kirk Robarge is often cited by papers focused on Carbohydrate Chemistry and Synthesis (6 papers), Computational Drug Discovery Methods (4 papers) and Melanoma and MAPK Pathways (4 papers). Kirk Robarge collaborates with scholars based in United States, China and France. Kirk Robarge's co-authors include Fillmore Freeman, Dale L. Boger, Robert L. Yauch, Frédéric J. de Sauvage, Stephen E. Gould, Richard Goldsmith, Brent Blackburn, Zora Modrušan, Thomas Januario and Dan Sutherlin and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Kirk Robarge

26 papers receiving 954 citations

Peers

Countries citing papers authored by Kirk Robarge

Since Specialization

Citations

This map shows the geographic impact of Kirk Robarge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Robarge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Robarge more than expected).

Fields of papers citing papers by Kirk Robarge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Robarge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Robarge. The network helps show where Kirk Robarge may publish in the future.

Co-authorship network of co-authors of Kirk Robarge

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk Robarge. A scholar is included among the top collaborators of Kirk Robarge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk Robarge. Kirk Robarge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists 2015 ·Bioorganic & Medicinal Chemistry Letters ·Benjamin P. Fauber, Alberto Gobbi, Kirk Robarge, Aihe Zhou, (unknown), Jianhua Cao, Yuzhong Deng, Céline Eidenschenk, Christine Everett, (unknown), Julie A. Hawkins, Adam R. Johnson, Hank La, Maxine Norman, Gary Salmon, (unknown), Wenjun Ouyang, Wei Tang, Harvey Wong	58
2	Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479 2014 ·Bioorganic & Medicinal Chemistry Letters ·Kirk Robarge, Wendy Lee, Charles Eigenbrot, Mark Ultsch, Christian Wiesmann, Robert A. Heald, Steve Price, Joanne F. M. Hewitt, Philip S. Jackson, Pascal Savy, Brenda Burton, Edna F. Choo, Jodie Pang, Jason Boggs, (unknown), (unknown), (unknown)	32
3	Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase 2014 ·Bioorganic & Medicinal Chemistry Letters ·Benjamin P. Fauber, Peter S. Dragovich, Jinhua Chen, Laura Corson, Charles Z. Ding, Charles Eigenbrot, Sharada S. Labadie, Shiva Malek, David Peterson, Hans E. Purkey, Kirk Robarge, Steve Sideris, Mark Ultsch, BinQing Wei, Ivana Yen, Qin Yue, Aihe Zhou	17
4	Discovery and preclinical development of vismodegib 2014 ·Expert Opinion on Drug Discovery ·Stephen E. Gould, Jennifer A. Low, James C. Marsters, Kirk Robarge, Lee L. Rubin, Frédéric J. de Sauvage, Daniel P. Sutherlin, Harvey Wong, Robert L. Yauch	54
5	A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Wendy Lee, Daniel F. Ortwine, Philippe Bergeron, Kevin Lau, (unknown), Shiva Malek, Jim Nonomiya, Zhonghua Pei, Kirk Robarge, Stephen Schmidt, Steve Sideris, Joseph P. Lyssikatos	26
6	Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions 2012 ·Drug Metabolism and Disposition ·Edna F. Choo, Marcia Belvin, Jason Boggs, Yuzhong Deng, Klaus P. Hoeflich, Justin Q. Ly, Mark Merchant, Christine Orr, Emile G. Plise, Kirk Robarge, (unknown), Robert Kassees, (unknown), (unknown), Stuart H. Johnston	28
7	502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623 2012 ·European Journal of Cancer ·Edna F. Choo, Marcia Belvin, (unknown), (unknown), (unknown), (unknown), Jason Boggs, Emile G. Plise, Kirk Robarge, Mark Zak	2
8	Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance 2010 ·Cancer Research ·Gerrit J.P. Dijkgraaf, Bruno Alicke, Lasse Weinmann, Thomas Januario, Kristina West, Zora Modrušan, Dan Burdick, Richard Goldsmith, Kirk Robarge, Dan Sutherlin, Suzie J. Scales, Stephen E. Gould, Robert L. Yauch, Frédéric J. de Sauvage	293
9	Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor 2010 ·Xenobiotica ·Edna F. Choo, Marcia Belvin, Jocelyn Chan, Klaus P. Hoeflich, Christine Orr, Kirk Robarge, Xiaoye Yang, Mark Zak, Jason Boggs	17
10	Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor 2009 ·Xenobiotica ·Harvey Wong, (unknown), (unknown), Jason Halladay, Jane R. Kenny, Hanson La, James C. Marsters, Emile G. Plise, Patrick J. Rudewicz, Kirk Robarge, Young G. Shin, Susan Wong, (unknown), S. Cyrus Khojasteh	47
11	A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo 2005 ·Journal of Biological Chemistry ·Alan G. Olivero, Charles Eigenbrot, Richard Goldsmith, Kirk Robarge, Dean R. Artis, John A. Flygare, Thomas E. Rawson, Daniel P. Sutherlin, Saloumeh Kadkhodayan, Maureen H. Beresini, Linda O. Elliott, (unknown), David W. Banner, Mark Ultsch, Ulla M. Marzec, Stephen R. Hanson, Canio J. Refino, Stuart Bunting, Daniel Kirchhofer	36
12	Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists 1998 ·Bioorganic & Medicinal Chemistry ·Kirk Robarge, Michael S. Dina, Todd C. Somers, Arthur Lee, Thomas E. Rawson, Alan G. Olivero, (unknown), Robert R. Webb, Kenneth J. Weese, Ignacio Aliagas, Brent Blackburn	11
13	Stability of alkoxycarbonylamidine prodrugs. 1998 ·Pharmaceutical Research ·Zahra Shahrokh, Eric Wai Ming Lee, Alan G. Olivero, (unknown), Kirk Robarge, Arthur Lee, (unknown), Brent Blackburn, Michael F. Powell	7
14	Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form 1998 ·Thrombosis and Haemostasis ·Nishit B. Modi, Sherron Bullens, (unknown), Michael T. Lipari, Kirk Robarge, Brent Blackburn, Maureen H. Beresini, (unknown), Beat Steiner, Stuart Bunting, Canio J. Refino	22
15	From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold 1994 ·Journal of the American Chemical Society ·Robert S. McDowell, Brent Blackburn, Thomas R. Gadek, Lawrence R. McGee, Thomas E. Rawson, Mark E. Reynolds, Kirk Robarge, Todd C. Somers, Eugene D. Thorsett	82
16	Mono-N-alkylation of anthranilamides via quinazolinones. An efficient synthesis of G5598, a benzodiazepine dione gpIIbIIIa antagonist 1994 ·Tetrahedron Letters ·Robert R. Webb, Peter L. Barker, (unknown), Mark E. Reynolds, Kirk Robarge, Brent Blackburn, (unknown), Kenneth J. Weese	29
17	Stereoselectivity in electrophile-mediated intramolecular cyclizations of hept-2-enitols 1989 ·The Journal of Organic Chemistry ·Fillmore Freeman, Kirk Robarge	18
18	Stereoselectivity in the electrophile-mediated cyclization of 2,3,5-tri-O-benzyl-1,2-dideoxy-d-arabino-hex-1-enitol. A stereocontrolled synthesis of 1-amino-2,5-anhydro-3,4,6-tri-O-benzyl-1-deoxy-d-glucitol 1987 ·Carbohydrate Research ·Fillmore Freeman, Kirk Robarge	30
19	Epimerization at C-2 during the Wittig reaction of 2,3,5-tri-O-benzyl-d-ribose and methylidenetriphenylphosphorane 1986 ·Carbohydrate Research ·Fillmore Freeman, Kirk Robarge	22
20	Electrophile-mediated cyclizations of 6-O-benzyl-1,2-di- deoxy-3,4-O-isopropylidene-d-ribo-hex-1-enitol to derivatives of 2,5-anhydro-6-O-benzyl-3,4-O-isopropylidene-d-altro-hexitol 1985 ·Carbohydrate Research ·Fillmore Freeman, Kirk Robarge	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact